![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amicus Therapeutics Inc | NASDAQ:FOLD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.17 | -1.72% | 9.70 | 9.49 | 10.71 | 9.88 | 9.585 | 9.82 | 2,197,892 | 23:56:20 |
“Since the Company’s inception, it has been our commitment to serve the needs of the rare disease community in extraordinary ways,” stated Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc. “Our annual ESG report reinforces our dedication to patients, and also outlines our obligation to support the needs of those beyond providing next-generation therapies. Our investment in corporate responsibility encompasses our philanthropic endeavors, mission-focused and inclusive culture, environmental stewardship, and strong business ethics and integrity. These core tenets, along with our shared sense of purpose, allow us to meaningfully engage with the rare disease community, and we look forward to building upon this foundation and promise to communicate our progress regularly and transparently.”
Amicus’ 2024 ESG initiatives are consistent with those identified by the Sustainability Accounting Standards Board (SASB) for the biotechnology and pharmaceuticals sector as well as several United Nations (UN) Sustainable Development Goals which most closely align with our patient-dedicated mission.
Highlights from the 2024 ESG Report:
Environment. Committed to practicing environmental responsibility and identifying and implementing sustainability objectives in our operations, and with our manufacturing and supply partners, to achieve a reduction in greenhouse gas (GHG) emissions.
Patients. Continued to prioritize our patient-focused mission to support individuals and families affected by rare disease, meet the unmet needs of the rare disease community, and support full access to education, diagnosis, medication, and service provision for rare diseases.
Employees. Progressed and enhanced our transparent, inclusive, and collaborative culture to give employees the tools and resources to grow personally and professionally while ensuring we can meaningfully engage with the global rare disease community.
Governance. Maintained a strong culture of business ethics and integrity to ensure that the Company is managed for the long-term benefit of all our stakeholders.
To access the full 2024 ESG Report, please visit www.amicusrx.com/responsibility/environmental-social-governance/.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information, please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors: Amicus Therapeutics Andrew FaughnanVice President, Investor Relationsafaughnan@amicusrx.com(609) 662-3809
Media: Amicus Therapeutics Diana Moore Head of Global Corporate Affairs and Communicationsdmoore@amicusrx.com(609) 662-5079
FOLD-G
1 Year Amicus Therapeutics Chart |
1 Month Amicus Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions